Mumbai, India: With the objective of raising awareness about mental health, global pharma major Lupin Limited (Lupin) announced that it is partnering with Shaan, famous Indian playback singer, for the re-launch of Shaan’s iconic hit song, ‘Tanha Dil Tanha Safar’ nationally today. The audio release of the song is now available on YouTube.
According to the World Health Organization (WHO) report, globally it is estimated that 5% of adults suffer from depression. To add on, in the wake of the Coronavirus pandemic, there have been a surge in the number of people being diagnosed with depression.
At Lupin, we have actively involved in raising awareness about mental health. Where words fail, music takes over as the most powerful means of expression, and that is why we have partnered with Shaan to re-launch the iconic song ‘Tanha Dil Tanha Safar’. While this song track focuses on a serious issue, it still has magic and soulfulness that can help people through a difficult time.
Speaking on the occasion, Mr. Rajeev Sibal, President – India Region Formulations (IRF) at Lupin, said “Mental health signs are often overlooked. Lupin aims to emphasize the importance of mental health as an integral part of living a healthy and balanced life. Our #SayYesToLife campaign aims to raise awareness about mental health.”
“We are delighted to have partnered with Shaan for the re-launch of the iconic song, Tanha Dil. Through the song, we intend to reflect the reality of mental health struggles. and break down the barrier to help people understand mental health conditions better,” he added.
Commenting on the association, Indian playback singer Shaan said, “I am pleased to have Lupin’s support for this initiative. I hope ‘Tanha Dil’ will bring peace and hope to millions of people and help address the societal stigma around the issue of mental health.”
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.
Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
For further information or queries please contact:
Head – Corporate Communications